Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at the Peter Doherty Institute of Infection and Immunity (Doherty Institute), in ...

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.

When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...

Breast cancers at all stages are defined by the structure of their genomes, researchers find. Targeting these processes early is likely to offer unexpected therapeutic avenues.

Breast cancers can be classified into subgroups that hint at the aggressiveness of the cancer and the likelihood that the ...

Chemotherapy for breast cancer may be more effective during specific stages of the menstrual cycle, according to data from ...

UCR scientists have developed new light-sensitive chemicals that can radically improve the treatment of aggressive cancers ...

Savita Dandapani, MD, PhD, discusses the rationale behind a study evaluating the combination of radium-223, hormone therapy, and SBRT in metastatic castration-sensitive prostate cancer.

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

Mayo Clinic, Mount Sinai and Huntsman Cancer Insitute are delivering services from chemotherapy to imaging in cancer patients ...

The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.